SCHEMBL616739

SCHEMBL616739

O=C(O)C(=O)Nc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 2/20 0.75
PTPN1 P18031 1/20 0.75
GPR35 Q9HC97 1/20 0.74
SMN1; SMN2 Q16637 2/20 0.64
TP53 P04637 1/20 0.64
EPHX1 P07099 1/20 0.64
TSHR P16473 1/20 0.64
EPHX2 P34913 1/20 0.64
CDK9 P50750 1/20 0.64
CLK4 Q9HAZ1 1/20 0.64
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
NAPRT Q6XQN6 1/20 0.58
HSD17B10 Q99714 1/20 0.58
CYP19A1 P11511 2/20 0.58
NPC1 O15118 2/20 0.55
PKM P14618 2/20 0.55
RAB9A P51151 2/20 0.55
CASP3 P42574 1/20 0.54
SENP7 Q9BQF6 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29742566 0.97 PTPN11 (0.72) PTPN11PTPN1GPR35SMN1; SMN2TP53
Ammonia Solution, Strong SCHEMBL11058615 0.97 PTPN11 (0.72) PTPN11PTPN1GPR35SMN1; SMN2TP53
Hydrochloric Acid SCHEMBL6245252 0.97 PTPN11 (0.72) PTPN11PTPN1GPR35SMN1; SMN2TP53
SCHEMBL11682238 0.91 PTPN11 (0.70) PTPN11PTPN1GPR35SMN1; SMN2TP53
SCHEMBL10495628 0.89 PTPN11 (0.74) PTPN11PTPN1GPR35MEN1KMT2A
Benzene SCHEMBL28977956 0.89 SMN1; SMN2 (0.70) PTPN11PTPN1GPR35SMN1; SMN2TP53
SCHEMBL57554 0.89 SMN1; SMN2 (0.70) PTPN11PTPN1GPR35SMN1; SMN2TP53
SCHEMBL2823028 0.86 PTPN1 (1.00) PTPN11PTPN1GPR35SMN1; SMN2MEN1
SCHEMBL11400184 0.85 GPR35 (1.00) PTPN11PTPN1GPR35MEN1KMT2A
Hydrazine SCHEMBL28432690 0.84 SMN1; SMN2 (0.64) PTPN11PTPN1GPR35SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 618 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340748-A1 Ultraviolet Light Stable Color-Changing Systems CHROMATIC TECHNOLOGIES, INC. (US) 2025-11-06 US claimed
EP-4608796-A1 PROCESS FOR THE SYNTHESIS OF METHOXY SUBSTITUTED BENZALDEHYDE COMPOUNDS Syngenta Crop Protection AG (CH) 2025-09-03 EP claimed
US-12359083-B2 Ultraviolet light stable color-changing systems CHROMATIC TECHNOLOGIES, INC. (US) 2025-07-15 US claimed
WO-2025088891-A1 POLYURETHANE RESIN-FORMING COMPOSITION, COATING AGENT SET, COATING FILM, AND METHOD FOR FORMING COATING FILM 東ソー株式会社 2025-05-01 WO claimed
CN-119823008-A Preparation method of 4-methylsulfonyl phenylacetic acid 浙江东亚药业股份有限公司 2025-04-15 CN claimed
WO-2024089225-A1 PROCESS FOR THE SYNTHESIS OF METHOXY SUBSTITUTED BENZALDEHYDE COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2024-05-02 WO claimed
WO-2024048447-A1 HEAT-SENSITIVE RECORDING BODY 大阪シーリング印刷株式会社 2024-03-07 WO claimed
CN-111995569-B Preparation method of cyclin-dependent kinase inhibitor intermediate 成都博腾药业有限公司 2023-12-05 CN claimed
CN-117069611-A Preparation method of 1- (2, 4, 6-trichlorophenyl) propan-2-one O-methyl oxime 浙江工业大学 2023-11-17 CN claimed
US-20220154024-A1 Ultraviolet Light Stable Color-Changing Systems CHROMATIC TECHNOLOGIES, INC. (US) 2022-05-19 US claimed
CN-112314611-A Use of oxanilic acid for controlling flea beetles 河北谷之润科技有限公司 2021-02-05 CN claimed
CN-111995569-A Preparation method of cyclin-dependent kinase inhibitor intermediate 成都博腾药业有限公司 2020-11-27 CN claimed
CN-103421489-B A kind of fluorescent material of superelevation quantum yield and application thereof JILIN UNIVERSITY (CN) 2015-11-11 CN claimed
CN-103421489-A Fluorescent material with ultrahigh quantum yield and application of fluorescent material UNIV JILIN 2013-12-04 CN claimed
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2004-07-22 US claimed
EP-1397340-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-03-17 EP claimed
WO-2002098850-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-12-12 WO claimed
CN-1097593-A Aqueous drug composition having property of reversible thermosetting gelation WAKAMOTO PHARMA CO LTD (JP) 1995-01-25 CN claimed
EP-0086746-B1 PHENYLAMINO-OXO-ACETIC ACIDS AND THEIR ESTERS AS HERBICIDAL ANTIDOTES FOR THE PROTECTION OF CULTIVATED PLANTS CIBA-GEIGY AG (CH) 1986-07-30 EP claimed
EP-0086746-A1 Phenylamino-oxo-acetic acids and their esters as herbicidal antidotes for the protection of cultivated plants CIBA-GEIGY AG (CH) 1983-08-24 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors CTSS, CTSB, CTSE PTPN11 2951/4885PTPN1 2698/4885GPR35 3831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.